InsiderSignal.AI

InsiderSignal.ai

PRLD - Prelude Therapeutics Inc

Insider Purchase by Orbimed Advisors LLC (Dir, 10%)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Orbimed Advisors LLC, serving as Dir, 10% owner at Prelude Therapeutics Inc (PRLD), purchased 2,815,315 shares at $4.44 per share, for a total transaction value of $12,499,999.00. Following this transaction, Orbimed Advisors LLC now holds 1,652,426 shares of PRLD.

This purchase represents a 242.00% decrease in Orbimed Advisors LLC's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, April 21, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 23, 2026, 2 days after the trade was made.

Prelude Therapeutics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Orbimed Advisors LLC

Dir, 10%

OrbiMed Advisors LLC is a leading healthcare-focused investment firm headquartered in New York City, founded in 1989 as the successor to Mehta & Isaly by Samuel Isaly.[[1]](https://fintool.com/app/research/funds/private-equity/orbimed-advisors-llc)[[3]](https://en.wikipedia.org/wiki/OrbiMed) Specializing in public and private investments across biopharmaceuticals, medical devices, diagnostics, digital health, and healthcare services, the firm manages approximately $20 billion in assets under management (AUM) with a global team of over 150 professionals across 12 locations.[[2]](https://www.orbimed.com)[[1]](https://fintool.com/app/research/funds/private-equity/orbimed-advisors-llc) OrbiMed invests globally in innovative healthcare companies from early-stage startups to large multinationals, supporting over 500 portfolio companies and backing more than 130 venture-backed IPOs.[[2]](https://www.orbimed.com) As a corporate insider listed as 'Dir.' at Sionna Therapeutics, Inc. (SION), OrbiMed has recently engaged in trading activities there, consistent with its active 13F filings showing a $4 billion portfolio as of June 30, 2025, with top holdings including Sinovac Biotech, Boston Scientific, and Eli Lilly.[[1]](https://fintool.com/app/research/funds/private-equity/orbimed-advisors-llc)[[4]](https://whalewisdom.com/filer/orbimed-advisors-llc)

View full insider profile →

Trade Price

$4.44

Quantity

2,815,315

Total Value

$12,499,999.00

Shares Owned

1,652,426

Trade Date

Tuesday, April 21, 2026

3 days ago

SEC Filing Date

Thursday, April 23, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Prelude Therapeutics Inc

Company Overview

No company information available
View news mentioning PRLD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5882554

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime